381 related articles for article (PubMed ID: 27193833)
21. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
22. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
Zhang J; Wang S; Kern S; Cui X; Danner RL
J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
[TBL] [Abstract][Full Text] [Related]
24. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
Dietlein F; Kalb B; Jokic M; Noll EM; Strong A; Tharun L; Ozretić L; Künstlinger H; Kambartel K; Randerath WJ; Jüngst C; Schmitt A; Torgovnick A; Richters A; Rauh D; Siedek F; Persigehl T; Mauch C; Bartkova J; Bradley A; Sprick MR; Trumpp A; Rad R; Saur D; Bartek J; Wolf J; Büttner R; Thomas RK; Reinhardt HC
Cell; 2015 Jul; 162(1):146-59. PubMed ID: 26140595
[TBL] [Abstract][Full Text] [Related]
25. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
26. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
27. Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition.
Lange L; Hemmerich P; Spänkuch B
Oncotarget; 2015 Sep; 6(28):25801-14. PubMed ID: 26317649
[TBL] [Abstract][Full Text] [Related]
28. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line.
Matsui TA; Sowa Y; Murata H; Takagi K; Nakanishi R; Aoki S; Yoshikawa M; Kobayashi M; Sakabe T; Kubo T; Sakai T
Int J Oncol; 2007 Oct; 31(4):915-22. PubMed ID: 17786325
[TBL] [Abstract][Full Text] [Related]
29. Molecular interactions of polo-like kinase 1 in human cancers.
Weng Ng WT; Shin JS; Roberts TL; Wang B; Lee CS
J Clin Pathol; 2016 Jul; 69(7):557-62. PubMed ID: 26941182
[TBL] [Abstract][Full Text] [Related]
30. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins.
de Carné Trécesson S; Guillemin Y; Bélanger A; Bernard AC; Preisser L; Ravon E; Gamelin E; Juin P; Barré B; Coqueret O
J Biol Chem; 2011 Apr; 286(15):12825-38. PubMed ID: 21292770
[TBL] [Abstract][Full Text] [Related]
31. Defeat mutant KRAS with synthetic lethality.
Pang X; Liu M
Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
[TBL] [Abstract][Full Text] [Related]
32. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
33. 5'-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells.
Kim SA; Kim SW; Chang S; Yoon JH; Ahn SG
Cancer Lett; 2009 Feb; 274(1):72-7. PubMed ID: 18926623
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.
Degenhardt Y; Greshock J; Laquerre S; Gilmartin AG; Jing J; Richter M; Zhang X; Bleam M; Halsey W; Hughes A; Moy C; Liu-Sullivan N; Powers S; Bachman K; Jackson J; Weber B; Wooster R
Mol Cancer Ther; 2010 Jul; 9(7):2079-89. PubMed ID: 20571075
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
Park US; Park SK; Lee YI; Park JG; Lee YI
Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
[TBL] [Abstract][Full Text] [Related]
36. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
37. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Chen Z; Cheng K; Walton Z; Wang Y; Ebi H; Shimamura T; Liu Y; Tupper T; Ouyang J; Li J; Gao P; Woo MS; Xu C; Yanagita M; Altabef A; Wang S; Lee C; Nakada Y; Peña CG; Sun Y; Franchetti Y; Yao C; Saur A; Cameron MD; Nishino M; Hayes DN; Wilkerson MD; Roberts PJ; Lee CB; Bardeesy N; Butaney M; Chirieac LR; Costa DB; Jackman D; Sharpless NE; Castrillon DH; Demetri GD; Jänne PA; Pandolfi PP; Cantley LC; Kung AL; Engelman JA; Wong KK
Nature; 2012 Mar; 483(7391):613-7. PubMed ID: 22425996
[TBL] [Abstract][Full Text] [Related]
38. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
[TBL] [Abstract][Full Text] [Related]
40. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
